Onderzoeker
Timothy Devos
- Disciplines:Immunologie
Affiliaties
- Moleculaire Immunologie (Rega Instituut) (Labo)
Lid
Vanaf1 jan 2019 → Heden - Tracheale Transplantatie (Labo)
Lid
Vanaf1 jan 2012 → 31 dec 2018 - Onderzoeksgroep Nefrologie en Niertransplantatie (Afdeling)
Lid
Vanaf1 okt 2001 → 30 sep 2005
Projecten
1 - 4 of 4
- Identificatie van neutrofielen als therapeutische doelwitten in de ontwikkeling en progressie van BCR::ABL1 negatieve myeloproliferatieve stoornissenVanaf4 okt 2023 → HedenFinanciering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
- Nier stam-/progenitorcellen als nier-specifieke celtherapieVanaf1 okt 2021 → HedenFinanciering: Fonds Recuperatie Fiscale Vrijstelling, BOF - projecten
- Nier stam-/progenitorcelllen als een potente bron van niergerichte celtherapie.Vanaf22 sep 2021 → HedenFinanciering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
- Herstel van weefselregeneratie bij patiënten met een viscerale graft-versus-hostziekte.Vanaf1 jan 2015 → 31 dec 2021Financiering: H2020 - Gezondheid, demografische verandering en welzijn
Publicaties
31 - 40 van 124
- Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myelogenous Leukaemia: A Retrospective Study and Review of the Literature(2021)
Auteurs: Nancy Boeckx, Timothy Devos, Peter Vandenberghe, Gregor Verhoef
Pagina's: 52 - 58 - Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies(2021)
Auteurs: Laurent Godinas, Yannick Van Herck, Natalie Lorent, Daan Dierickx, Geert Meyfroidt, Lore Vanderbeke, Valentijn Vergote, Katrien Lagrou, Peter Verhamme, Joost Wauters, et al.
Pagina's: 1100 - 1105 - Multipotent mesenchymal stromal cells in kidney transplant recipients: The next big thing?(2021)
Auteurs: Timothy Devos, Ben Sprangers
- A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial(2020)
Auteurs: Timothy Devos, Tatjana Geukens, Anne Luyten, Piet Maes, Katleen Vandenberghe, Geert Verbeke, Laurens Liesenborghs, Peter Verhamme, Geert Meyfroidt
- A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial (vol 21, 981, 2020)(2020)
Auteurs: Timothy Devos, Tatjana Geukens, Alexander Schauwvlieghe, Kevin K Arien, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniel Desmecht, David Grimaldi, et al.
- Convalescent Plasma against COVID-19: A broad-spectrum therapeutic approach for emerging infectious diseases(2020)
Auteurs: Marijn Thijssen, Timothy Devos, MahmoudReza Pourkarim
- One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study(2020)
Auteurs: Timothy Devos
- Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group(2020)
Auteurs: Timothy Devos
Pagina's: E1 - E3 - Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available(2019)
Auteurs: Timothy Devos
Pagina's: 3493 - 3502 - Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium(2019)
Auteurs: Timothy Devos, Gregor Verhoef
Pagina's: 197 - 207